Oral bioavailability of a low molecular weight heparin using a polymeric delivery system

被引:109
作者
Hoffart, Valerie [1 ]
Lamprecht, Alf [1 ]
Maincent, Philippe [1 ]
Lecompte, Thomas [1 ]
Vigneron, Claude [1 ]
Ubrich, Nathalie [1 ]
机构
[1] INSERM, U734, EA 3452, Pharmaceut Technol Lab, F-54001 Nancy, France
关键词
low molecular weight heparin; oral absorption; nanoparticles;
D O I
10.1016/j.jconrel.2006.03.020
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Low molecular weight heparins (LMWHs) are the standards of anticoagulant for the prevention of deep vein thrombosis (DVT) in patients undergoing arthroplasty and abdominal surgery. However, LMWHs are so far only administered by parenteral route. Thus, they are usually replaced by oral warfarin for outpatient therapy. Since warfarin has a slow onset and high incidence of drug-drug interaction, there is a great need for the development of an oral LMWH formulation. LMWH (tinzaparin)-loaded nanoparticles prepared with a blend of a polyester and a polycationic polymethacrylate by the double emulsion method were administered orally in fasted rabbits. The plasma tinzaparin concentration was measured by a chromogenic anti-factor Xa assay. After oral administration of two doses of tinzaparin-loaded nanoparticles (200 and 600 anti-Xa U/kg), the oral absorption was observed between 4 and 10 or 12 h, with a delayed onset of action ranging from 3 to 4 h. Mean absolute bioavailabilities were 51% and 59% for the two tested doses. We now report that the encapsulation of tinzaparin into nanoparticles is likely to contribute to its oral efficacy with an anticoagulant effect prolonged up to 8 h. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:38 / 42
页数:5
相关论文
共 50 条
[21]   Porous balloon delivery of low molecular weight heparin in the dog coronary artery [J].
Baumbach, A ;
Oberhoff, M ;
Rubsamen, K ;
Jochims, K ;
Herdeg, C ;
Kranzhofer, A ;
Safer, A ;
Karsch, KR .
EUROPEAN HEART JOURNAL, 1996, 17 (10) :1538-1545
[22]   Biomimetic Solid Lipid Nanoparticles for Oral Bioavailability Enhancement of Low Molecular Weight Heparin and Its Lipid Conjugates: In Vitro and in Vivo Evaluation [J].
Paliwal, Rishi ;
Paliwal, Shivani R. ;
Agrawal, Govind P. ;
Vyas, Suresh P. .
MOLECULAR PHARMACEUTICS, 2011, 8 (04) :1314-1321
[23]   Using low molecular weight heparin in special patient populations [J].
Wendy Lim .
Journal of Thrombosis and Thrombolysis, 2010, 29 :233-240
[25]   Low molecular weight heparin in children [J].
Albisetti, M ;
Andrew, M .
EUROPEAN JOURNAL OF PEDIATRICS, 2002, 161 (02) :71-77
[26]   Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system [J].
Ashar, Fareeaa ;
Mohammed, Asif Ansari Shaik ;
Selvamuthukumar, S. .
PLOS ONE, 2024, 19 (09)
[27]   pH-responsive thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery: in vitro and in vivo evaluation [J].
Fan, Bo ;
Xing, Yang ;
Zheng, Ying ;
Sun, Chuan ;
Liang, Guixian .
DRUG DELIVERY, 2016, 23 (01) :238-247
[28]   Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers [J].
Hoffart, V ;
Ubrich, N ;
Lamprecht, A ;
Bachelier, K ;
Vigneron, C ;
Lecompte, T ;
Hoffman, M ;
Maincent, P .
DRUG DELIVERY, 2003, 10 (01) :1-7
[29]   Low molecular weight heparin-loaded polymeric nanoparticles: Formulation, characterization, and release characteristics [J].
Hoffart, V ;
Ubrich, N ;
Simonin, C ;
Babak, V ;
Vigneron, C ;
Hoffman, M ;
Lecompte, T ;
Maincent, P .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (09) :1091-1099
[30]   Synthesis and Evaluation of Pegylated Dendrimeric Nanocarrier for Pulmonary Delivery of Low Molecular Weight Heparin [J].
Shuhua Bai ;
Fakhrul Ahsan .
Pharmaceutical Research, 2009, 26 :539-548